Esperion Therapeutics, Inc.
ESPR
$3.14
-$0.01-0.32%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -52.45% | 92.93% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -52.45% | 92.93% | |||
| Cost of Revenue | -17.25% | -24.61% | |||
| Gross Profit | -64.05% | 297.21% | |||
| SG&A Expenses | 4.08% | -0.99% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.17% | -14.45% | |||
| Operating Income | -107.72% | 955.84% | |||
| Income Before Tax | -139.57% | 303.21% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -140.75% | 297.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -140.75% | 297.34% | |||
| EBIT | -107.72% | 955.84% | |||
| EBITDA | -107.69% | 958.34% | |||
| EPS Basic | -138.36% | 267.33% | |||
| Normalized Basic EPS | -137.30% | 272.23% | |||
| EPS Diluted | -146.11% | 239.21% | |||
| Normalized Diluted EPS | -144.85% | 243.24% | |||
| Average Basic Shares Outstanding | 6.20% | 17.91% | |||
| Average Diluted Shares Outstanding | -11.67% | 41.76% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||